drugset / Trial / NCT06048302
PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
Non-randomizedParallel-groupOpen-labelOther
Summary
To investigate the safety and pharmacokinetics in patients with moderate hepatic impairment compared to healthy participants after a single oral dose of obicetrapib (10 mg).
Timeline
- Start
- 2023-11-30
- Primary completion
- 2024-03-12
- Completion
- 2024-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obicetrapib | Small molecule | 10 mg | Oral |
Indications
No indication recorded.